CrushSCI.com
提供学术论文选刊润色服务
Signal Transduction and Targeted Therapy 期刊封面 医学
返回期刊列表

Review Cycle Records

Signal Transduction and Targeted Therapy

Springer SCIE OA
2026新锐 1区2025中科院 1区 TOP2025 JCR Q1
213.9平均天数
257中位天数
8最短天数
385最长天数
4282025发文量

Paper Review Records

全部论文审稿周期

15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

41 天

EBV-driven Gate–License–Amplify circuit in multiple sclerosis pathogenesis

作者Yuxin Li; Xiaofei Shi; Yuxiao Zhang; Mu-Sheng Zeng; Qian Zhong; Wanli Liu

作者单位1. School of Management & Engineering, Nanjing University, Nanjing, China; 2. Jiangsu Key Laboratory of Digital Finance, Suzhou, China; 3. State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, Ministry of Education Key Laboratory of Protein Sciences, Tsinghua University, Beijing, China; 4. Department of Rheumatology and Immunology, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China; 5. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

PDF源文件 DOI 网页
257 天

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

作者Linong Ji; Leili Gao; Ben Li; Mei Liu; Xianghua Zhang; Chao Meng

作者单位1. Department of Endocrinology, Peking University People’s Hospital, Beijing, China; 2. Chengdu Vincentage Pharma Co. Ltd., Chengdu, China; 3. Department of General Medicine, Yueyang Central Hospital, Yueyang, China; 4. Department of General Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

PDF源文件 DOI 网页
302 天

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

作者Jia Yu; Anwen Xiong; Qiming Wang; Jianhua Chen; Hongrui Niu; Chengzhi Zhou; Panwen Tian; Wu Zhuang; Jie Li; Jing Wang; Junguo Lu; Kangsheng Gu; Jinsheng Shi; Jun Guo; Yonghui Di; Dongqing Lv; Debin Sun; Liming Cao; Zhixiong Yang; Jingxun Wu; Liyun Miao; Yueyin Pan; Chong Li; Xiaohong Wu; Jie Yin; Xiang Wang; Meili Sun; Miao He; Shundong Cang; Haohui Fang; Ping Chen; Min Zhang; Xinmei Yang; Hui Zhao; Jian Feng; Xuezhen Ma; Sheng Hu; Jian Lu; Xin Zhao; Zhixiang Zhuang; Yilan Sun; Xu Sun; Bing Yu; Chaonan Zhu; Jianghua Chen; June Xu; Kai Wang; Caicun Zhou

作者单位1. Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; 2. Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou, China; 3. Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China; 4. Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; 5. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 6. Department of Respiratory and Critical Care Medicine, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China; 7. Department of Thoracic Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China; 8. Department of Respiratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, China; 9. Department of Respiratory Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 10. Department of Respiratory Medicine, Nantong Tumor Hospital, Nantong, China; 11. Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; 12. Department of Oncology, Cangzhou People’s Hospital, Cangzhou, China; 13. Department of Medical Oncology, Xingtai People’s Hospital, Hebei, China; 14. Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai, China; 15. Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China; 16. Respiratory Department, Lishui Central Hospital, Lishui, China; 17. Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, China; 18. Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China; 19. Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China; 20. Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China; 21. Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China; 22. Department of Respiration, First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China; 23. Department of Medical Oncology, The Affiliated Hospital of Jiangnan University (The Fourth People’s Hospital in Wuxi City), Wuxi, China; 24. Department of Respiratory and Critical Care Medicine, General Hospital of the Eastern Theatre of the Chinese People’s Liberation Army, Nanjing, China; 25. Department of Oncology, Xuzhou Central Hospital, Xuzhou, China; 26. Department of Oncology, Jinan Central Hospital, Jinan, China; 27. Oncology Department, Deyang People’s Hospital, Deyang, China; 28. Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, China; 29. Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, China; 30. Department of Oncology, Yancheng NO.1 People’s Hospital, Yancheng, China; 31. Department of Pulmonary and Critical Care Medicine, Ganzhou People’s Hospital, Ganzhou, China; 32. Department of Radiation Oncology, The First Hospital of Jiaxing, Jiaxing, China; 33. Department of Respiratory Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, China; 34. Department of Respiratory and Critical Care Medicine, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 35. Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, China; 36. Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan, China; 37. Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China; 38. Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital and The First Affiliated Hospital with Nanjing Medical University, Nanjing, China; 39. Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China; 40. Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People’s Hospital, Hangzhou, China; 41. Hangzhou Zhongmei Huadong Pharmaceutical Company, Hangzhou, China; 42. Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China; 43. Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China; 44. Department of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

PDF源文件 DOI 网页
365 天

Translational insights and clinical challenges of targeting cancer stem cells

作者Mehreen Ahmed; Amr Al-Haidari; Shruti Agarwal; Jianmin Sun; Emma U. Hammarlund; Lars Rönnstrand; Kenneth J. Pienta; Özge Tatli; Julhash U. Kazi

作者单位1. Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2. Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden; 3. Lund University Cancer Centre (LUCC), Lund University, Lund, Sweden; 4. Department of Surgery and Cancer, Imperial College London, London, UK; 5. Department of Urology, University of Rochester Medical Center, Rochester, USA; 6. Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India; 7. School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China; 8. Tissue Development and Evolution (TiDE), Department of Experimental Medical Science, Lund University, Lund, Sweden; 9. Division of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 10. The Cancer Ecology Center, Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, USA; 11. Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Türkiye

PDF源文件 DOI 网页
276 天

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics

作者Cody A. Loy; Yijun Gu; Samuel C. Kim; Mariam V. Mohagheghi; Noah B. Trask; Marina Suarez-Pizarro; Lisa E. Wagar; Claudia A. Benavente; Darci J. Trader

作者单位1. Department of Pharmaceutical Sciences, University of California, Irvine, USA; 2. Robert A. Mah Molecular Innovation Center, University of California, Irvine, USA; 3. Department of Physiology and Biophysics, University of California, Irvine, USA; 4. Adeline Yen Mah Vaccine Center, University of California, Irvine, USA; 5. Institute for Immunology, University of California, Irvine, USA; 6. Center for Virus Research, University of California, Irvine, USA; 7. Department of Developmental and Cell Biology, University of California, Irvine, USA; 8. Chao Family Comprehensive Cancer Center, University of California, Irvine, USA; 9. Deparment of Chemistry, University of California, Irvine, USA

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。